3x Logo white
Accelerating the diagnosis of genetic repeat expansion ("GRE") diseases

Failure to diagnose GRE diseases delays patient care and endangers future generations. 

3X Genetics is developing testing platforms to accelerate the diagnosis of GRE diseases. 

Our first target is Myotonic Dystrophy, the most common form of Muscular Dystrophy.

3x autoclave

About Us

In 2022, after two sons experienced nine years of misdiagnosis of Myotonic Dystrophy, Kevin Donahue founded 3X Genetics to accelerate the diagnosis of genetic diseases to optimize patient care and protect future generations. 


Platforms

Diagnostic Platform

Coming in 2024, 3X Genetics has developed a platform for providing diagnostic tests to medical professionals. This platform offers low-cost diagnosis of genetic repeat expansion disorders, starting with Myotonic Dystrophy.

GRE Panel

By 2026, using breakthrough nanopore sequencing technology, 3X Genetics plans to sell a single low-cost test to screen for multiple GRE diseases. The 3X GRE Platform will also accurately measure repeat expansions to enable the correlation of symptoms to repeat length.

3x woman w microscope

Team

MANAGEMENT TEAM:

Kevin Donahue, CEO

Mr. Donahue is an experienced technologist and entrepreneur. Mr. Donahue holds several patents related to optics and illumination. He is the father of two boys with Myotonic Dystrophy. He has a BS in chemical engineering from WPI and an MS from The Harvard T.H. Chan School of Public Health.

Micheal S. Manak PhD, President and CSO

Michael’s skill set combines a deep domain knowledge in molecular systems biology, biochemistry, and cell biology. Most recently Michael was the Vice President of Research and Development for Cellanyx Diagnostics, of Boston, Massachusetts. Michael has a Ph.D. in Molecular and Cellular Biology, from the University of Florida, Gainesville and a B.S. in Microbiology and Cell Science, University of Florida, Gainesville.

Hari Nair PhD, FAACC, MBA. CLIA Lab Director

Hari is an experienced CLIA lab director, who has built and certified a molecular diagnostic lab. He has proven expertise in understanding, interpreting, and the implementation of laboratory capabilities compliant with CLIA/COLA/CAP/FDA. Hari provided leadership during COVID epidemic by providing high-volume diagnosis, personally swabbing over 3,000 patients. His professional experience includes more than 20 years in bioanalytical product and service development. Hari has a Ph.D. in Mass Spectrometry of Biomolecules and MBA from Yale.

Michael Browne, VP of Business Development

Michael has twenty years of business development experience. He is a diligent market strategist and business planner with exceptional communication and alliance development skills. Most recently he was the co-founder and Vice President of OptoGlo Inc. Michael has a BS in Computer Science and a BA in Music from Sonoma State University.

SCIENTIFIC ADVISORY BOARD:

John Quackenbush, PhD, Professor, Harvard T.H. Chan School of Public Health

John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of theDepartment of Biostatistics at the Harvard T.H. Chan School of Public Health, Professor in the Channing Division of Network Medicine, and Professor at the Dana-Farber Cancer Institute.

Steven Oldenburg, PhD

Recently, Dr. Oldenburg was a Vice President at Fortis Life Sciences where he managed the diagnostic division. Previously, he was the founder and CEO of nanoComposix, where Steve pioneered the use of nanoparticles in diagnostic test strips. Dr. Oldenburg has a Doctor of Science in Applied Physics from Rice University.

Christopher Sassetti, PhD, Professor, University of Massachusetts Medical School Dr. Sassetti leads a diverse group of geneticists, immunologists and microbiologists focused primarily on efforts to improve treatments for tuberculosis. He is currently a leader in an $11,000,000 NIH funded project focused on tuberculosis treatments, has been a Hughes Foundation Investigator, and was recently elected to the American Academy of Microbiology.

Mark Tarnopolsky PhD, Professor, Department of Pediatrics and the Division Head ofNeuromuscular and Neurometabolic Disorders, McMaster University

Dr. Tranopolsky is a graduate of McMaster University and has been a faculty member since 1996. Dr. Tarnopolsky focuses his innovative research on mitochondrial diseases, muscle disorders, and other neurometabolic disorders. Dr. Tarnopolsky holds a Chair in Neuromuscular Disorders from McMaster Children’s Hospital/Hamilton Health Sciences Foundation and is recognized as an international leader in researching neuromuscular and neurometabolic disorders.

Meni Wanunu PhD, Professor, Department of Physics ansd Biomedical Engineering, Northeastern University.

Dr. Wanunu, leads Wanunu Labs, at Northeastern University, which is interested in the mechanisms by which small physical and/or chemical changes to biomolecules lead to global changes in cell fate. Dr Wanunu’s interests include combining optical measurements with electrical measurements to probe transport through a variety of nanopore systems. Meni received a PhD in Chemistry/Materials and Interfaces, from the Weizmann Institute of Science.

BOARD OF DIRECTORS:

Kevin Donahue, Chairman

Allen Downey PhD, Professor of Computer Engineering, Olin College of Engineering Dr. Allen Downey teaches classes in software engineering and data science as well as physical modeling and simulation He is the author of several textbooks; they include Think Python, ThinkStats, and Modeling and Simulation in Python. Dr. Downey received his Ph.D. in computer science from the University of California/Berkeley in 1997, with a dissertation on operating system support for large-scale parallel computation. His undergraduate and master’s degrees are from the Civil Engineering department at MIT. He is the author of Probably Overthinking It, a blog about Data Science and Statistics.

Richard Kimo Baldwin, PhD, Vice President of Research, Seer, San Diego, CA

Richard Baldwin was born in Canberra, Australia and after completing his undergraduate education in Melbourne he returned to Canberra to complete a PhD at the Australian National University in organometallic chemistry with time in both Italy and Germany. He went on to complete postdocs at both UC Irvine and UC Davis in California where his interests in the interface between biology and nanomaterials began. Dr. Baldwin currently works in a VP role at Seer, with a team developing nanoparticles to capture the human proteome from biological samples for both discovery and diagnostics.

Connect with 3X!

To learn more about 3X Genetics, submit our web form or contact info@3xgenetics.com

Contact Us

Directions:

Copyright © 2024. All Rights Reserved. 3x Genetics Inc.
Scroll to Top